Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
Alzprotect designs and develops innovative therapeutic solutions for these diseases.
Objective: to halt neurodegeneration and restore certain brain functions
An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
News
ALZPROTECT Receives U.S. FDA Fast Track Designation for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)
Fast Track designation follows U.S. IND clearance and is designed to facilitate development and expedite review of AZP2006 in PSP
Lille, France, August 24, 2026 — Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). The designation was granted under IND 169279 following Alzprotect’s request. The FDA concluded that AZP2006 meets the criteria for Fast Track
ALZPROTECT Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)
Lille, France — May 19th 2026 — Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States.
“FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer “We can now expand